Bonura Frank
St. Catherine of Siena Medical Center, Smithtown, NY 11787, USA.
Postgrad Med. 2009 Jul;121(4):5-17. doi: 10.3810/pgm.2009.07.2021.
Osteoporosis is a major public health concern, resulting in increased fracture risk. Osteoporosis-related fractures impose a considerable economic burden on health care systems, and the disease has severe, debilitating consequences if left untreated. Measures for osteoporosis prevention should begin at childhood and include balanced nutrition, physical activity, and avoidance of risk factors such as smoking. In adulthood, early recognition of osteoporosis followed by timely and effective management can reduce fracture risk. However, the rates of screening and treatment for osteoporosis are low, even in patients who have sustained a fragility fracture. Comprehensive fracture risk assessment should be part of routine patient care. Nonpharmacologic strategies to improve or maintain bone health should always be implemented, but many patients also need pharmacologic intervention to achieve adequate fracture protection. Several pharmacologic therapies are currently available, and when choosing from the available options, clinicians should consider the efficacy and safety profiles of each therapy as well as the individual patient's needs and overall health. Ideally, therapy should satisfy multiple criteria: fracture protection across multiple skeletal sites; rapid onset of action to maximize the timing of fracture protection; and minimal side effects with proven long-term safety.
骨质疏松症是一个重大的公共卫生问题,会导致骨折风险增加。与骨质疏松症相关的骨折给医疗保健系统带来了相当大的经济负担,如果不进行治疗,该疾病会产生严重的、使人衰弱的后果。骨质疏松症的预防措施应从儿童时期开始,包括均衡营养、体育活动以及避免吸烟等风险因素。在成年期,早期识别骨质疏松症并随后进行及时有效的管理可以降低骨折风险。然而,骨质疏松症的筛查和治疗率很低,即使在发生脆性骨折的患者中也是如此。全面的骨折风险评估应成为常规患者护理的一部分。应始终实施改善或维持骨骼健康的非药物策略,但许多患者也需要药物干预以实现足够的骨折预防。目前有几种药物疗法可供选择,在从可用选项中进行选择时,临床医生应考虑每种疗法的疗效和安全性概况以及个体患者的需求和整体健康状况。理想情况下,治疗应满足多个标准:对多个骨骼部位提供骨折保护;迅速起效以最大限度地延长骨折保护时间;副作用最小且长期安全性得到证实。